

Application No. 10/848,737

Docket No.: V9661.0080

**AMENDMENTS TO THE CLAIMS**

The following list of claims replaces any prior claims in the application:

1-19. (Cancelled).

20. (Currently amended) An isolated nucleic acid molecule consisting ~~essentially~~ of the nucleotide sequence of SEQ ID NO:4 and/or a complement of SEQ ID NO:4, ~~or at least 10 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:4 and/or a complement of said contiguous nucleotides.~~

21. (Previously presented) The nucleic acid molecule of claim 20 wherein said nucleic acid molecule is double-stranded.

22. (Previously presented) The nucleic acid molecule of claim 21 wherein said nucleic acid molecule is a RNA.

23. (Cancelled).

24. (Previously presented) A vector comprising a nucleic acid molecule of claim 20.

25. (Previously amended) An isolated host cell containing the vector of claim 24.

26. (Currently amended) An immunogenic formulation comprising an immunogenically effective amount of the nucleic acid molecule of claim 20 operably linked to one or more control elements, and a pharmaceutically acceptable carrier.

27-28. (Cancelled).

29. (Previously presented) A kit comprising a container containing the immunogenic formulation of claim 26.

Application No. 10/848,737

Docket No.: V9661.0080

30-32. (Cancelled).

33. (Previously presented) A method for inhibiting SARS viral infection or replication in a cell comprising administering to the cell an effective amount of the nucleic acid molecule consisting essentially of the nucleotide sequence of SEQ ID NO:4 and/or a complement of SEQ ID NO:4, or at least 10 or more contiguous nucleotides of the nucleotide sequence of SEQ ID NO:4 and/or a complement of said contiguous nucleotides.